, medical expert
Last reviewed: 19.10.2021

All iLive content is medically reviewed or fact checked to ensure as much factual accuracy as possible.

We have strict sourcing guidelines and only link to reputable media sites, academic research institutions and, whenever possible, medically peer reviewed studies. Note that the numbers in parentheses ([1], [2], etc.) are clickable links to these studies.

If you feel that any of our content is inaccurate, out-of-date, or otherwise questionable, please select it and press Ctrl + Enter.

According to statistics, among all known diseases the most unfavorable prognosis is characterized by circulatory system disorders and oncological formations.

The pathology of the circulatory system is often associated with a violation of hemorheological blood parameters. In the treatment of this type of disorder, Eberkinase is sometimes used, a fibrinolytic agent capable of dissolving intravascular thrombi.

Indications Eberkinaza

Indications for the use of the drug can be:

Release form

Produced in the form of powdered substance of 750 thousand FE or 1,500,000 FE in sealed corked bottles of 10 ml.


The active substance of the preparation combines with plasminogen in stoichiometric proportions of 1: 1, which favors the transition of plasminogen molecules to plasmin. The latter, in turn, is capable of dissolving fibrin fibers from blood clots and blood clots, and also provoking a decrease in the functions of fibrinogen and other plasma proteins that participate in blood clotting.

Due to the properties of Eberkinase, it is effective to dissolve thrombi over their entire surface, and also to restore the lumen of blood vessels and to activate blood circulation in them, the use of the drug has significantly reduced the number of lethal cases with myocardial infarction and thromboembolism of the pulmonary artery.


The maximum concentration of the drug is already observed in the first 45 minutes. After the infusion introduction, the effect of fibrinolysis can persist for several hours; thrombin time is extended during the day. The effect of a single dosage lasts from 48 to 72 hours, the effect of thrombolysis (thrombosis) is actively supplemented by fibrinogen cleavage processes.

Biotransformation occurs in the liver by hydrolysis (no identification data on metabolites).

The main amount of active substance decomposes into peptides and is excreted by the urinary system.

Dosing and administration

Powdered substance is diluted in 5 ml of water for injection: all actions are carried out with caution, preventing the formation of foam in the solution. The obtained concentrate is transferred to a bottle with saline solution or 5% dextrose solution for intravenous drip infusion. Dosage and the number of administrations are determined by the physician individually.

  • In acute myocardial infarction, the drug is administered intravenously or intracardiacally. Complex treatment includes the administration of Eberkinase in the peripheral vein at a dosage of 1.5 million FU for one hour. Intracardiac administration is performed using a coronary catheter: 20,000 FE are used, while also carrying out intravenous administration.
  • In venous thrombosis, the agent is used for intravenous administration with a catheter. The introduction is carried out in the inguinal vein, subclavian, or in the vein of the shin. The drug is administered at the earliest possible time from the moment of thrombus formation; dosage is selected depending on the size and degree of resorption of the thrombus.
  • With pulmonary embolism, intravenously 250,000 FE of the drug are administered intravenously over a half an hour. It may be necessary to re-introduce the drug.

As a preventive measure for the emergence of recurrent thrombosis, heparin can be prescribed.

trusted-source[3], [4]

Use Eberkinaza during pregnancy

The use of this fibrinolytic drug is contraindicated in the first half of pregnancy due to the fact that it can promote fibrinous (fibrinoid) deposits along the edges of trophoblast villi and disorders of postimplantation development of the embryo.

During the second half of pregnancy, the drug is administered only on absolute indications.

According to some experimental data, the active substance of the drug does not penetrate the placental barrier, so dosage in the second half of pregnancy can be standard.


Among the main contraindications to the use of the drug can be identified as follows:

  • allergic susceptibility to any constituent of Eberkinase;
  • tendency to bleeding;
  • confirmed data on the presence of hemorrhagic diathesis;
  • erosion and peptic ulcer disease;
  • inflammatory processes in the intestine;
  • fresh open and closed wounds, bruises, fractures;
  • aneurysms;
  • neoplasms with the effect of germination in the vascular tissue;
  • oncology of the brain or metastatic formations;
  • chronic and severe cases of hypertension;
  • disorders of the vascular wall in diabetes mellitus;
  • inflammatory diseases of the endocardium and pericardium;
  • defect of the mitral valve, atrial flutter;
  • open form of tuberculosis;
  • cavernous lung disease;
  • septic conditions;
  • rehabilitation period after open surgical operations;
  • recent internal biopsy;
  • 90-day period after cerebral hemorrhage;
  • first half of pregnancy;
  • a ten-day postpartum period;
  • 2 weeks after an induced abortion;
  • presence of permanent catheterization;
  • cirrhosis of the liver, significant atherosclerosis;
  • acute appendicitis.

It is not recommended to administer the drug when treated with other fibrinolytic drugs during the last year.

Side effects Eberkinaza

Among the side effects during the period of taking the drug are the most frequent bleeding:

  • from any damaged areas of tissues and mucous membranes (gums, digestive tract, urogenital system);
  • defeat of the spleen;
  • various types of hemorrhages, including intradermal, intramuscular, cerebral;
  • occurrence of arrhythmia;
  • the phenomenon of pulmonary edema with intracardiac administration of the drug;
  • thrombus rupture;
  • increase in the rate of erythrocyte sedimentation;
  • anaphylaxis with too intensive administration of the drug;
  • dyspeptic phenomena, the possibility of developing allergic reactions up to anaphylactic shock.

trusted-source[1], [2]


Symptoms of overdose may be an increase in the severity of adverse events and the occurrence of multiple or single bleeding.

Therapeutic methods in case of an overdose are reduced to stopping bleeding (if any), prescribing anti-fibrinolytic drugs, and to recovering blood loss. If necessary, conduct symptomatic therapy.

A mandatory condition for the treatment of overdose is the complete withdrawal of Eberkinazy.

Interactions with other drugs

The oppression of blood coagulation properties and increased danger of hemorrhages is enhanced by the simultaneous use of Eberkinase with heparin, indirect anticoagulants (neodicumarine, syncumar, escusin), pyrimidine derivatives, acetylsalicylic acid preparations.

It is not recommended to combine the administration of Eberkinase and plasma-substituting solutions.

trusted-source[5], [6], [7]

Storage conditions

The drug should be stored in the refrigerator. Optimum temperature for storage - from 2 to 8 degrees. Limit children's access to the drug.

trusted-source[8], [9]

Shelf life

Shelf life:

  • a bottle of 1.5 million FE - up to 2 years;
  • a bottle of 750 thousand FE - up to 3 years.

trusted-source[10], [11]


To simplify the perception of information, this instruction for use of the drug "Eberkinaza" translated and presented in a special form on the basis of the official instructions for medical use of the drug. Before use read the annotation that came directly to medicines.

Description provided for informational purposes and is not a guide to self-healing. The need for this drug, the purpose of the treatment regimen, methods and dose of the drug is determined solely by the attending physician. Self-medication is dangerous for your health.

Translation Disclaimer: The original language of this article is Russian. For the convenience of users of the iLive portal who do not speak Russian, this article has been translated into the current language, but has not yet been verified by a native speaker who has the necessary qualifications for this. In this regard, we warn you that the translation of this article may be incorrect, may contain lexical, syntactic and grammatical errors.

You are reporting a typo in the following text:
Simply click the "Send typo report" button to complete the report. You can also include a comment.